Pemfexy (Pemetrexed) Patent Expiration, LOE Window & CMS Spending

Pemfexy (Pemetrexed) by Eagle: FDA Orange Book core substance LOE 2035-10-28 (last listed 2036-02-19), 0 AB generics, $11.7M 2024 CMS Part D & Medicaid spend, and $4,453 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEagle
FDA Application & PathwayN209472 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2035-10-28
Last Listed Patent or Exclusivity Date2036-02-19
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$11.7M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$11.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($4,453 intro WAC)